Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

PMID:
30487236
2.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

3.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.

J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.

4.

Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death.

Chang KH, Multani PS, Sun KH, Vincent F, de Pablo Y, Ghosh S, Gupta R, Lee HP, Lee HG, Smith MA, Shah K.

Mol Biol Cell. 2011 May;22(9):1452-62. doi: 10.1091/mbc.E10-07-0654. Epub 2011 Mar 9.

5.

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI.

Leuk Res. 2009 Aug;33(8):1055-61. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23.

PMID:
19108889
6.

Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.

Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI.

Leuk Res. 2009 Jun;33(6):769-74. doi: 10.1016/j.leukres.2008.09.020. Epub 2008 Oct 30.

PMID:
18976810
7.

Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.

Theuer CP, Leigh BR, Multani PS, Allen RS, Liang BC.

Biotechnol Annu Rev. 2004;10:265-95. Review.

PMID:
15504711
8.

No clinical evidence for CD4+ cell depletion caused by rituximab.

Saville MW, Benyunes MC, Multani PS.

Blood. 2003 Jul 1;102(1):408; author reply 408-9. No abstract available.

9.

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS.

J Clin Oncol. 2003 Apr 1;21(7):1263-70.

PMID:
12663713
11.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA.

J Clin Oncol. 2002 Aug 1;20(15):3262-9.

PMID:
12149300
12.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA.

Blood. 2002 Jun 15;99(12):4336-42.

13.

Melanoma.

Haluska FG, Multani PS.

Cancer Chemother Biol Response Modif. 1999;18:470-88. Review.

PMID:
10800498
14.

A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.

Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM.

Clin Cancer Res. 1999 Sep;5(9):2392-8.

15.
16.

Monoclonal antibody-based therapies for hematologic malignancies.

Multani PS, Grossbard ML.

J Clin Oncol. 1998 Nov;16(11):3691-710. Review.

PMID:
9817291
17.

Staging Laparotomy in the Management of Hodgkin's Disease: Is It Still Necessary?

Multani PS, Grossbard ML.

Oncologist. 1996;1(1 & 2):41-55.

Supplemental Content

Loading ...
Support Center